High-risk strains of human papillomavirus (HPV) such as HPV type 16 (HPV16) and HPV18 are causative agents of most human cervical carcinomas. E6, one of the oncogenes encoded by HPV16, possesses a number of biological and transforming functions. We have previously shown that the binding of E6 to host apoptotic proteins such as tumor necrosis factor (TNF) R1, the adaptor protein FADD, and procaspase 8 results in a significant modification of the normal flow of apoptotic events. For example, E6 can bind to and accelerate the degradation of FADD. In addition, full-length E6 binds to the TNF R1 death domain and can also bind to and accelerate the degradation of procaspase 8. In contrast, the binding of small splice isoforms known as E6* results in the stabilization of procaspase 8. In this report, we propose a model for the ability of HPV16 E6 to both sensitize and protect cells from TNF as well as to protect cells from Fas. We demonstrate that both the level of E6 expression and the ratio between full-length E6 and E6* are important factors in the modification of the host extrinsic apoptotic pathways and show that at high levels of E6 expression, the further sensitization of U2OS, NOK, and Ca Ski cells to TNF-mediated apoptosis is most likely due to the formation of a pseudo-death-inducing signaling complex structure that includes complexes of E6 proteins.
High-risk strains of human papillomavirus (HPV) such as HPV type 16 (HPV16) and HPV18, are the causative agents of most cases of human cervical carcinomas (23) . Two oncogenes encoded by these viruses, E6 and E7, are best known for their ability to inactivate the tumor suppressors p53 and Rb, respectively (34) . HPV16 E6 (E6) mediates a rapid, ubiquitin-dependent degradation of the tumor suppressor p53, and the resulting loss of p53 clearly contributes to the oncogenic potential of high-risk HPVs. In addition to accelerating the degradation of p53, E6 possesses numerous other biological and transforming activities (28) . These activities result from the binding of E6 to cellular proteins that are involved in a number of cellular functions such as the regulation of transcription and DNA replication, epithelial organization and differentiation, cell-cell adhesion, polarity, proliferation control, DNA repair, apoptosis, and immune evasion (36) .
One important host response to viral infection is the activation of one or more apoptotic pathways, a process that is often carried out through members of the tumor necrosis factor (TNF) superfamily. To overcome the elimination of infected cells through apoptosis, viruses have developed numerous ways to modify the normal course of apoptotic events (reviewed in references 12 and 14) . Apoptosis mediated by members of the TNF superfamily is initiated by the binding of ligands to their corresponding receptors. This interaction leads to the recruitment of adaptor proteins and initiator caspases to the death domain (DD) of receptors, resulting in the formation of a death-inducing signaling complex (DISC). Following DISC formation, the cleavage of procaspases and dissociation of active initiator caspases from the DISC lead to downstream events of the cell death pathway (1, 4, 16) .
The expression of the E6 oncogene from high-risk types of papillomavirus modifies the cellular response to extrinsic apoptotic triggers. In host cells, E6 is expressed as a full-length 16-kDa protein as well as its splice isoform E6*, a protein of 7 kDa (9, 17, 31, 32) . We have previously shown that the binding of E6 to host apoptotic proteins such as TNF R1, the adaptor protein FADD, and procaspase 8 results in a significant modification of the normal flow of apoptotic events. E6 can protect cells from apoptosis induced by Fas ligand (10) and by TRAIL (15) as a result of the binding of full-length E6 to the death effector domain (DED) of FADD and the consequent acceleration of its degradation. At low levels of expression, E6 can also protect cells from TNF. This protection is probably a result of the binding of full-length E6 to the TNF R1 DD (11) and/or to the procaspase 8 DED (9) . An interesting and somewhat paradoxical observation is that while full-length E6 binds to and accelerates the degradation of procaspase 8, the binding of E6* to procaspase 8 results in its stabilization (9) . This balance between the destabilization and stabilization of procaspase 8, mediated by the full-length and shortened isoforms, respectively, undoubtedly contributes to the alteration of the cellular response to members of the TNF superfamily.
A further intriguing and seemingly contradictory observation was that E6 not only protects cells from TNF (6) but can also sensitize them (27, 37) , especially at high levels of E6 expression (7) . Cells derived from cervical cancers with inte-grated HPV16 or HPV18 genomes, such as Ca Ski, SiHa, and HeLa cells, also demonstrate a wide range of cellular responses to TNF-, Fas-, and TRAIL-induced apoptosis, from sensitivity to resistance (7, 21, 22) . In addition to differences in their responses to triggers of extrinsic apoptosis, Ca Ski and SiHa cells also respond differently to treatments that trigger intrinsic apoptosis in transformed cells (3, 19, 26, 33, 35) . For example, Ca Ski cells were sensitive while SiHa cells were resistant to apoptosis in the absence of cell anchorage (25) . Also, lower concentrations of hsp90 inhibitors were required to cause cell death in Ca Ski cells than in SiHa or HeLa cells (35) . In this report, we present a set of observations that may explain some of the paradoxical behaviors observed in cells derived from cervical cancers following exposure to radio-or chemotherapeutic treatments (19, 33) . In particular, we propose a model for the ability of HPV16 E6 to both sensitize and protect cells from TNF and to protect cells from Fas. We demonstrate that both the level of E6 expression and the ratio between full-length E6 (E6 large) and E6* are important factors in the modification of host extrinsic apoptotic pathways and show that at high levels of E6 expression, the further sensitization of U2OS cells and of keratinocytes, the natural host cells for HPVs, to TNF-mediated apoptosis is likely due to the formation of a pseudo-DISC structure that includes complexes of E6 proteins.
MATERIALS AND METHODS
Reagents. Lyophilized human recombinant TNF-␣ and biotinylated TNF-␣ (R&D Systems) as well as ␣-Fas monoclonal antibodies (clone CH-11) (Medical and Biological Laboratories Co., Ltd., Nagoya, Japan) were dissolved into phosphate-buffered saline. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) at a concentration of 5 mg/ml, cycloheximide (Cx) (Sigma-Aldrich) at 5 mg/ml, and doxycycline (Dox) (Clontech) at 1 mg/ml were also dissolved in phosphate-buffered saline. MG132 (Calbiochem) was dissolved into dimethyl sulfoxide to yield a 50 mM solution.
Monoclonal antibodies directed against the HPV16 E6 N or C terminus were obtained from Euromedex (France), and rat polyclonal peroxidase-coupled ␣-hemagglutinin (HA) antibodies and monoclonal ␣-HA were obtained from Roche. Monoclonal ␣-␤-actin, polyclonal ␣-Flag horseradish peroxidase (HRP)-coupled antibodies, monoclonal ␣-c-myc-HRP-coupled antibodies, and ␣-Flag agarose were obtained from Sigma-Aldrich. Monoclonal ␣-TNF R1 antibodies and polyclonal ␣-FADD, monoclonal ␣-green fluorescent protein (GFP), and monoclonal ␣-E7 were purchased from Santa Cruz Biotechnology. Monoclonal ␣-p53 (DO-7) (Novacastra Labs, United Kingdom) and monoclonal ␣-caspase 8 from BD Biosciences and Pharmingen were also used for immunoblot analysis.
Cell culture. U2OS cells, derived from a human osteosarcoma, as well as Ca Ski and SiHa cells, derived from cervical carcinomas, were obtained from the ATCC. U2OS cells and its derivatives were cultured in McCoy's 5A medium (Invitrogen), Ca Ski and SiHa cells were cultured in modified Eagle medium (Invitrogen), and normal oral keratinocyte (NOK) cells were grown in KFSM (Invitrogen). Medium for U2OS, Ca Ski, and SiHa cells was supplemented to contain 10% fetal bovine serum (Invitrogen), penicillin (100 u/ml), and streptomycin (100 g/ml) (Sigma-Aldrich). Medium for U2OS cells expressing E6 under the control of the tet-responsive element was supplemented by Tet-fetal bovine serum (BD Biosciences, Clontech). The description and production of stably transfected U2OS cell lines capable of expressing variable amounts of HA-E6, regulated by different concentrations of Dox present in medium, were described previously (10) . SiHa-derived stable cell lines expressing Flag-E6* as well as U2OS cells expressing Flag-wild-type E6 (E6wt) were obtained by transfection of the parental cells with plasmids pFlag (vector control), pFlag E6*, or pFlag E6wt followed by G418 selection for 2 to 3 weeks. Table 1 lists the cell lines created and used in this paper as well as those previously described (7, (9) (10) (11) .
Plasmids. Plasmids pE-1 (backbone of pEGFP-1; Clontech) and pTre-E6, expressing HA-tagged HPV16 E6, were cloned and described previously (10, 11) . The derivative plasmids, named pHA-E6AS, pHA-E6wt, pHA-E6large, and pHA-E6* and pTetE6wt, pTetE6 large, and pTetE6*, respectively, were also previously described.
Plasmid pFlagE6wt was obtained by cloning E6wt in frame with the Flag and c-myc tag into vector pFlag-myc CMV-22 (Sigma-Aldrich). Flag-E6wt was also cloned into the retroviral vector pLNCX (BD Biosciences, Clontech) prior to introduction into NOK cells. Retroviral stocks of pLNCX and pLNCX-FlagE6wt were produced by transient cotransfection with pLNCX and pLNCX-FlagE6wt along with pVSV-G, coding for the G glycoprotein of vesicular stomatitis virus, and then used for the infection of NOK cells. The production of retroviral stocks and infection of NOK cells were performed according to protocols provided by BD Biosciences (Clontech). In order to inhibit the expression of E6 large, the target short hairpin RNA (shRNA) sequence for E6 large, pSilsiE6large, and the scrambled sequence for the control, pSilCon, were cloned into the expression vector pSilencer 3.1 (Ambion). Plasmids pADcaspase 8 DED, pBDcaspase 8 DED, pAD FADD, p BD TNF R1 DD, and pAD TRADD were cloned and used to perform the mammalian two-hybrid assay as described previously (9, 11) . Plasmid pNF-B-Luc was purchased from BD Biosciences (Clontech).
Transfections. Transfections were carried out using Fugene VI (Roche) or TransIt-LT1 transfection reagent (MirusBio) as directed by the manufacturers. For transient transfections, cells were analyzed 40 to 48 h posttransfection. For stable transfections, clones were passaged into selection medium containing G418 (500 g/ml), hygromycin (100 g/ml), or puromycin (5 g/ml) as appropriate. Following 2 to 3 weeks of selection, individual clones were grown and analyzed for protein expression by immunoblotting and/or reverse transcription (RT)-PCR.
Treatment of cells with TNF and ␣-Fas. To measure cell survival or apoptosis following TNF-␣ or ␣-Fas treatment, cells were seeded into 96-well plates (1 ϫ 10 4 cells/well) and allowed to adhere overnight. TNF-␣ or ␣-Fas was then added in the presence of Cx, and the cells were incubated for 6 or 16 h prior to analysis, as described below.
To determine the ability of cells to accumulate increased levels of p53 following DNA damage, cells were treated with mitomycin C and assayed for the resulting p53 levels. Cells were seeded into 24-well plates (1 ϫ 10 5 cells/well) and allowed to adhere overnight. Approximately 24 h later, mitomycin C was added to a final concentration of 2 g/ml medium. After 16 h, cells were harvested, and the lysates were analyzed for p53 by enzyme-linked immunosorbent assay (ELISA) (described below).
To prevent the proteosomal degradation of proteins, cells were treated with MG132 at a concentration of 5 M for 16 h.
Cell viability and apoptosis assays. (i) MTT assay. The incubation medium was removed and exchanged for 80 l of fresh medium. Twenty microliters of MTT was then added (5 mg/ml stock), and cells were incubated at 37°C for 3 h. The medium was removed, and 150 l of dimethyl sulfoxide was added and allowed to incubate for 10 min. The solution was mixed by pipetting, and the absorbance of each well was determined at 490 nm.
(ii) CellTiter-Glo luminescent cell viability assay (Promega). Cells were treated with TNF or ␣-Fas in 100 l of medium. One hundred microliters of the substrate was then added to each well, and 10 min following lysis, the chemiluminescence was measured in 20 l of lysate.
(iii) Caspase-Glo 3/7 assay (Promega). To measure the activation of caspase 3/7, cells were seeded into a 96-well plate (1 ϫ 10 4 cells/well in 100 l of medium). After treatment with TNF or ␣-Fas, cells were combined with 20 l of 5ϫ passive lysis buffer (Promega). The activity of caspase 3/7 was measured in 20 l of lysate following the addition of 20 l of Caspase-Glo 3/7 reagent. Chemiluminescence was measured using a MicroLuminatPlus LB 96V luminometer obtained from Berhold Technologies.
Immunoblot assays. For immunoblot analysis, 10 6 cells were lysed in 100 l of Laemmli lysis buffer, and lysates were then sonicated and loaded onto a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. After the transfer of protein onto Immobilon P membranes (Millipore Corporation) and blocking of the membrane with 5% nonfat milk, primary antibodies were applied with Tris-buffered saline-Tween. After incubation with rocking (room temperature for 1 h), membranes were washed with Tris-buffered saline-Tween. Secondary ImmunoPure antibody (␣-mouse or ␣-rabbit) conjugated with HRP (Pierce) was applied, as appropriate, onto the membrane for 1 h, and the detection of signals was performed by using the chemiluminescent SuperSignal West Femto or Pico maximum-sensitivity substrate (Pierce).
Immunoprecipitation and coimmunoprecipitation. Cells (0.5 ϫ 10 6 to 5 ϫ 10 6 ) were lysed in 500 l of lysis buffer (11) , and cleared lysates were incubated with 40 l of ␣-Flag agarose (Sigma-Aldrich) at 4°C for 3 h with rotation. The ␣-Flag agarose was then washed three times with lysis buffer, followed by one wash with high-salt buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1 mM dithiothreitol) and one wash with buffer lacking NaCl. The precipitates were fractionated by 12% SDS-PAGE, and immunoblotting was performed as described above.
For coprecipitation of the pseudo-DISC, 2 ϫ 10 7 cells (UtetCon, UtetE6wt, NpLNCX, N E6wt#7, or Ca Ski cells) were treated with biotinylated TNF-␣ (2 g/ml) for 30 min and were lysed in 1 ml of lysis buffer. Cleared lysates were combined with 50 l of streptavidin agarose (Novogen) and incubated overnight at 4°C. The washes and fractionation of bound proteins were performed as described above for immunoprecipitation.
PCR. Total RNA was isolated using Trizol, and cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) according to manufacturer's protocols. Semiquantitative RT-PCR was performed using primers 5Ј-GCACC AAAAGAGAACTGCAATGT-3Ј and 5Ј-TGGGTTTCTCTACGTGTTCTTG AT-3Ј to detect both E6 isoforms. RT-PCR was performed as described previously (9) .
Quantitative real-time PCR to measure the levels of the E6 isoforms was conducted using primers designed as described previously by Hafner et al. (18) , along with the Absolute QPCR Sybr green kit according to the manufacturer's protocol (ABgene). Observed E6 isoform concentrations were normalized using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expression levels.
p53 ELISA. Cells were assayed for p53 by ELISA as described previously (38) . Cells treated or not treated with mitomycin C were lysed in lysis buffer. Monoclonal antibody pAB122 (hybridoma was obtained from the ATCC, and antibodies were purified from the culture medium using protein A-Sepharose) was used as the primary or capture antibody, and biotinylated goat ␣-p53 (R&D Systems) was used as the detection antibody. Each sample was measured in triplicate, and the results were normalized to the amount of protein present in each sample. The protein concentration in lysates was measured using the BioRad D c protein assay kit.
Development and use of the Tet-Off system. U2OS cells capable of expressing variable amounts of HA-E6, regulated by the level of Dox present in the medium, were created using the Tet-Off system (Clontech) according to the manufacturer's protocol, with some modifications (10) . Cultures of these cells were grown in the indicated concentrations of Dox for 2 days prior to use, and the indicated concentrations of Dox were maintained in the medium throughout each experiment.
Mammalian two-hybrid assay. The mammalian two-hybrid binding assay was performed essentially according to the manufacturer's instructions (Stratagene). Modifications of this protocol were described previously (9) . The indicated combinations of vectors were transfected into cells along with the pFR-Lucexpressing reporter plasmid and with pcDNA3 GFP in order to normalize for transfection efficiency. The relative binding affinity between two proteins was estimated based on the luciferase expression level normalized by the GFP expression level. Luciferase activity was measured by adding a substrate from a luciferase assay system (Promega) to cell lysates, and chemiluminescence was measured using a MicroLuminatPlus LB 96V luminometer from Berhold Technologies. GFP expression in cell lysates was estimated using an Flx 800 96-well plate reader (Bio-Tec Instrument Company).
NF-B activation assay. UtetE6wt cells (7 ϫ 10 4 cells/well) were seeded onto a 24-well plate in the presence of variable concentrations of Dox. The next day, cells were transfected with plasmid pNF-B-Luc. Forty-eight hours posttransfection, cells were treated either with Cx alone (5 g/ml) or with Cx plus TNF-␣ (5 ng/ml) for 1 h. The level of luciferase expression under the control of the NF-B response element was estimated by adding substrate from a luciferase assay system (Promega) to cell lysates. The resulting chemiluminescence was measured using a MicroLuminatPlus LB 96-V luminometer from Berhold Technologies. The activation of NF-B was calculated by dividing the reporter gene activity after Cx treatment along with TNF-␣ by the reporter gene activity after Cx treatment alone.
RESULTS
The level of E6 expression affects the cellular response to TNF and to ␣-Fas. We have previously reported that U2OS cells expressing high levels of E6, as regulated by the Tet-Off system, are sensitized to TNF-induced apoptosis, while cells expressing low levels of E6 are protected from TNF treatment. Meanwhile, at the same high levels of E6 expression that led to TNF sensitization, cells are protected from Fas-mediated apoptosis, with the degree of protection lessening as E6 levels are reduced (7) . In other words, this viral protein can modulate a host response in opposing directions, dependent only on the level of its expression (Fig. 1A) .
At the molecular level, we have also observed that at high levels of E6 expression, cells are characterized by increased amounts of procaspase 8 (9), lower levels of FADD (10), and lower levels of p53 ( Fig. 1B and 2D ) than non-E6-expressing cells, while at low levels of E6 expression, cells exhibit a decreased amount of procaspase 8 and nearly normal levels of FADD and p53 (9, 10) (Fig. 2D) . The level of TNF R1 does not change with the level of E6 expression (11) . Confirming our previous observations (7, (9) (10) (11) , Fig. 1B demonstrates that E6 expression affects the levels of procaspase 8, FADD, and p53 but not the level of TNF R1.
At high levels of E6 expression, binding between apoptotic partners is inhibited. To further explore the molecular basis for the E6-mediated changes in the cellular apoptotic response, we proceeded to estimate the binding between major partners involved at the initial steps of TNF-and Fas-induced apoptosis. For this set of studies, we utilized the same cell line as shown Fig. 1A and B, UtetE6wt, in which the level of E6 can be controlled by the amount of Dox added to the medium (Fig.  2E ). We also employed the mammalian two-hybrid assay, which allowed us to measure the binding among several sets of proteins that participate in signal transduction. If E6 were to bind to one or more of these partners, this could lead to changes in the binding affinity between them.
First, we examined the binding of TNF R1 to the adaptor protein TRADD, which is recruited to the receptor in response to TNF treatment. The results demonstrate that at high levels of E6 expression (0 ng/ml Dox), the interaction between the TNF R1 DD and TRADD is significantly reduced. This binding gradually increases as the level of E6 is reduced, leading to a reciprocal relationship between TNF R1/TRADD binding and the level of E6 ( Fig. 2A) . The recruitment of TRADD to TNF R1 also leads to the activation of the protective NF-B pathway. If the level of interaction between the TNF R1 DD and TRADD is indeed decreased by the presence of E6, the level of activation of the NF-B pathway should also be reduced. This prediction was tested by comparing the expression levels of the NF-B cis-acting enhancer element-controlled luciferase reporter gene in the presence and absence of TNF stimulation. The plasmid, plasmid pNFkB-Luc (Clontech), was transiently transfected into cells in which the level of E6 expression was regulated by the presence of variable levels of Dox in the medium. Consistent with our prediction, in cells expressing maximum levels of E6, the activation of the NF-B pathway was much lower than that in cells expressing lower levels of E6 (Fig. 2B) .
Another set of partners involved in the TNF-and Fas-mediated apoptotic signal transduction pathway is the procaspase 8 and FADD pair. Interactions between procaspase 8 and FADD lead to the formation of procaspase 8/procaspase 8 homodimers, which can then be activated and cleaved. Using an approach similar to that described above, we estimated the binding affinities of procaspase 8 both to FADD and to itself in cells with variable levels of E6 expression, from high to low. The results of this experiment (Fig. 2C ) demonstrate binding affinities between procaspase 8 and FADD and between procaspase 8 and procaspase 8 at high levels of E6 expression, which were gradually restored as the concentration of E6 was lowered. One measure of E6 activity is the level of p53, as E6 mediates its rapid degradation. Normally, p53 levels are increased following treatment with DNA-damaging agents such as mitomycin C, but this increase can be abrogated by the presence of HPV16 E6 (34) . As predicted, the lowest level of FIG. 1. High and low levels of E6 have opposing effects on cellular responses to TNF and to ␣-Fas and differentially affect levels of procaspase 8 and FADD. (A) High levels of E6 expression correspond to sensitization to TNF and protection from ␣-Fas, while low levels of E6 expression lead to protection from TNF. Cells stably transfected with HA-E6 under the control of the tet-responsive element (UtetE6wt) were cultured in the presence of the indicated concentrations of Dox and treated with TNF (5 ng/ml) or ␣-Fas (10 ng/ml) in the presence of Cx (5 g/ml) for 16 h. As a control, U2OS cells were also treated with TNF and ␣-Fas. Viability was measured using the MTT assay. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. (B) E6 alters the levels of p53, procaspase 8, and FADD but not those of TNF R1. UtetE6wt cells were grown in the presence or absence of 100 ng/ml Dox. Cell lysates were subjected to SDS-PAGE, and immunoblots were performed using antibodies against the indicated proteins. Prior to the detection of p53, cells were treated with mitomycin C (2 mg/ml) for 16 h before cell lysis (top). Procaspase 8 (second panel) and TNF R1 (sixth panel) expressions were normalized by blotting for ␤-actin (third and seventh panels, respectively). In the FADD experiment (fourth panel), pcDNA3-FADD was cotransfected into cells, along with pcDNA3-GFP, and the level of GFP was estimated in order to normalize for transfection efficiency (fifth panel). To detect the expression of the full-length and short (eighth panel) isoforms of E6, cells were treated with 5 M MG132 for 16 h prior to lysate preparation, and loading was normalized by blotting for ␤-actin (ninth panel).
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p53 following treatment with mitomycin C was observed at the highest concentration of E6, and the level of p53 increased as the level of E6 decreased (Fig. 2D ). The ability of the indicated concentrations of Dox in the medium to regulate E6 expression is shown in Fig. 2E . UtetE6wt cells expressing high levels of E6 (no Dox) are characterized by a high level of procaspase 8 and a reduced level of FADD (7) (Fig. 1B) . The protection from Fas-mediated apoptosis experienced by these cells could be explained by enhanced degradation of FADD; however, the reduction in FADD levels achieved in these experiments clearly did not inhibit apoptosis triggered by TNF. Instead, these cells became even more sensitive to TNF (Fig. 1A) . These data are consistent with previously reported data from our laboratory (9) indicating that FADD may not be required for apoptosis triggered by TNF. At low levels of E6 expression, the level of procaspase 8 was decreased, and the cells did become resistant to TNF (Fig. 1A and B) . Protection from TNF in this situation could be explained by the low level of procaspase 8. Interestingly, the level of expression of apoptotic proteins at high and To estimate the binding between TNF R1 and TRADD, procaspase 8 and procaspase 8, or procaspase 8 and FADD, the mammalian two-hybrid assay was performed. Sequences encoding the DD of TNF R1, procaspase 8 DED, FADD, and TRADD were cloned into the bait or prey plasmids of a mammalian two-hybrid assay kit (Stratagene). The bait and prey plasmids encoding the indicated proteins were transfected into UtetE6wt cells along with a reporter plasmid coding for firefly luciferase, and the expression of the luciferase gene was measured using luciferase assay substrate (Promega) by chemiluminescence. To measure the activation of NF-B, plasmid pNFB-luc (Clontech) was transfected into the cells, and 48 h later, cells were either untreated or treated with TNF (5 ng/ml) for 1 h. The level of luciferase expression was measured by chemiluminescence using luciferase assay substrate (Promega). The activation was calculated by dividing luciferase activity values for cells treated with TNF by values for untreated cells. The level of p53 after 16 h of mitomycin C treatment (2 g/ml) in cells expressing different levels of E6 (UtetE6wt) or not expressing E6 (Utet) was estimated by p53 ELISA (8, 38) . Cells were seeded into 24-well plates in triplicate in the presence of medium containing different concentrations of Dox. Each value was measured in triplicate, and the error bars represent the standard deviations of the means. OD405, optical density at 405 nm. (E) E6 large expression was estimated by immunoblotting using antibodies directed against the N terminus of E6.
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low levels of E6 expression does not necessarily correlate with data for binding (Fig. 2) . For example, procaspase 8 levels are highest at high levels of E6 expression (Fig. 1B) , but the level of formation of procaspase 8/procaspase 8 and procaspase 8/FADD complexes is very low under these conditions. It is worth noting that TNF-induced apoptosis proceeded readily under these conditions of low levels of procaspase 8 complexes (Fig. 1A) .
Both E6 large and E6* protect U2OS cells from TNF-induced apoptosis, while only E6 large protects cells from Fasinduced apoptosis. In human cells, E6wt produces three transcripts as a result of alternative splicing, which are translated into a full-length protein of approximately 16 kDa, E6 large, and two short proteins of approximately 7 kDa, E6*I and E6*II (Fig. 3A) . The latter two splice isoforms differ in the C-terminal 7 amino acids and appear as one band by immunoblot analysis. This pair of proteins was previously referred to as E6 small/E6* (9), and in this report, they will be referred to as E6*. Interestingly, the large and small isoforms of E6 have separable biological activities with respect to procaspase 8. E6 large is responsible for the accelerated degradation of procaspase 8, while the binding of E6* to procaspase 8 leads to its stabilization (9, 10).
As noted above ( Fig. 1 ) (9), the sensitization of E6-expressing U2OS cells to TNF-induced apoptosis correlates well with high levels of procaspase 8, and high levels of procaspase 8 are associated with high levels of E6* expression (9) . These observations led to the suggestion that E6* might be responsible for the sensitization of cells to TNF. To test this possibility, plasmids expressing only E6 large or E6* were constructed. To express only E6 large, the splice site was mutated such that only the full-length transcript was expressed from the gene. To obtain expression of E6* in the absence of E6 large, the 200-bp transcript coding for this isoform was cloned into an expression vector. U2OS cells were stably transfected with plasmids coding for FlagE6 large (pFlagE6large) or FlagE6* (pFlagE6*) or the vector control not coding for E6 (pFlag) and analyzed by immunoblotting (Fig. 3B ). This analysis indicated that only the full-length protein was produced from cells transfected with the splice site-mutated plasmid, and only E6* was expressed from the truncated gene. Cells from stably transfected pools were then treated with TNF or ␣-Fas. Unexpectedly, the results (Fig. 3C ) demonstrated that the expression of both E6 large and E6* protects cells from TNF-induced apoptosis, compared to a pool of control cells transfected with pFlag. No evidence of sensitization of cells to TNF was found. Interestingly, only those cells expressing Flag-E6 large exhibited resistance to ␣-Fas, consistent with our previously reported findings (10) . Similar results were obtained from experiments using a transient transfection system followed by the expression of pHA-E6 large or pHA-E6* in U2OS cells (data not shown).
To further verify that both E6 large and E6*, when expressed separately, did indeed lead to the protection of cells from TNF, we transfected U2OS cells with either pHA-E6 large or pHA-E6* (expression is shown in Fig. 3D ) and then expanded stable clones resulting from these transfections that stably expressed either HA-E6 large or HA-E6*. The cells derived from these clones were then treated with TNF or ␣-Fas, and the percentage of clones that were more resistant or more sensitive to TNF or ␣-Fas treatments compared to control cells not expressing E6 was determined (Fig. 3E ). Clones were considered to be more resistant or more sensitive if cell survival differed from that seen in the HA-E6 antisense (E6AS) pool by more than 5%. The results show that 81% of the clones expressing HA-E6 large were resistant to TNFinduced apoptosis, while 71.5% of these clones were resistant to ␣-Fas. Ninety-six percent of the stable clones expressing E6* were resistant to TNF treatment, while there was no clear effect of E6* on the response of transfected clones to treatment with ␣-Fas. Again, there was no evidence that either isoform of E6, when expressed alone, could sensitize cells to TNF. Together, these results led to the conclusion that both E6 large and E6*, when expressed individually in U2OS cells, caused the resistance of these cells to TNF-induced apoptosis. The expression of E6* did not further sensitize U2OS cells to TNF treatment, as had been initially expected. In addition, only E6 large could protect cells from ␣-Fas.
One interesting observation made in UtetE6wt cells following treatment with TNF was that very low levels of E6 expression appeared to be sufficient to protect cells from TNF (7). To verify and expand this observation, we created cell lines expressing E6 large (UtetE6L) and E6* (UtetE6*) in which the level of E6 expression could be regulated by the addition of Dox to the medium (Fig. 4A) . We predicted that the response of the UtetE6L cells to treatment with ␣-Fas would be regulated by Dox in a dose-dependent manner but that even very low levels of E6 expression in cells would be sufficient to cause resistance to TNF. To test this prediction, the cells were grown with different concentrations of Dox and treated with TNF and ␣-Fas. The measurement of cell viability (Fig. 4B, right) demonstrates that the cellular response of UtetE6L to treatment with ␣-Fas was indeed dose dependent, with higher levels of E6 large leading to more resistance. The expression of E6* did not affect the cellular response to ␣-Fas regardless of the level expressed. In the case of TNF treatment, however, we found that all tested levels of each of the two isoforms, E6 large and E6*, were equivalently protective (Fig. 4B, left) . It appears from these data that even the low levels of E6 large and E6* that are produced in the presence of high levels of Dox are sufficient to protect cells from TNF-induced apoptosis and that increasing the expression level does not further enhance this protection.
E6 large and E6* produce complexes when they are expressed together. The experiments described above suggest a paradox. Both E6 large and E6*, when separately expressed in mammalian U2OS cells, protect these cells from TNF-induced apoptosis. Neither isoform was shown to cause further sensitization ( Fig. 3 and 4) , a phenomenon readily observed in cells expressing high levels of the wild-type gene. This observation suggests that only when the two isoforms are expressed together can they sensitize cells to TNF and that this sensitization can be achieved only at high levels of E6 expression. It is known that E6* can bind to E6 large and that this binding inhibits the E6-mediated degradation of p53 (31, 32) . It seemed likely that complexes between E6 large and E6*, in one way or another, were participating in sensitizing cells to TNF. To determine whether complexes between E6 large and E6* could be produced in U2OS cells, and in order to maximize our ability to visualize such complexes if they were indeed produced, we generated high levels of E6 expression by transient 5 cells/well) were seeded into a six-well plate. Cells were then transfected with pFlag, pFlagE6large, and pFlagE6*, and stable pools were created following G418 selection. To demonstrate E6 expression in these pooled clones, cells were treated with MG132 (5 M) for 16 h. Cell lysates were subjected to SDS-PAGE, and E6 was detected by immunoblotting. (C) Response of E6-expressing, stable pools of U2OS cells to treatment with TNF and ␣-Fas. These pooled cells (1 ϫ 10 4 cells/well) were seeded onto a 96-well plate and were treated with TNF (5 ng/ml) or ␣-Fas (10 ng/ml) in the presence of Cx (5 g/ml) for 16 h the next day. Viability was measured using the MTT assay. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. The Student two-tailed t test was used to determine statistical significance, with " * " representing a level of confidence of Ͼ0.99. (D) Expression of E6wt, E6 large, and E6* in U2OS cells. U2OS cells were transfected with pHA-E6wt, pHA-E6 large, and pHA-E6*. Thirty-two hours posttransfection, cells were treated with MG132 (5 M) for 16 h. Cell lysates were subjected to SDS-PAGE, and E6 was detected by immunoblotting. (E). Cellular responses of stable cell lines expressing E6 large and E6* to TNF or to ␣-Fas treatment. Stable cell lines expressing HA-E6 large (n ϭ 30) or HA-E6* (n ϭ 18) were selected by G418 and isolated. A total of 1 ϫ 10 4 cells/well derived from each cell line were seeded into 96-well plates and treated with TNF (5 ng/ml) or ␣-FAS (10 ng/ml) in the presence of Cx (5 g/ml) for 16 h the next day. Viability was measured using the MTT assay. The viability of the individual stable cell lines was then compared with the viability of pooled UHA-E6AS cells. A cell line was considered to be resistant or sensitive if the cellular response to TNF or ␣-Fas differed by more than 5% compared to the pooled UHA-E6AS cells. The percentages of cell lines with the indicated phenotypes with respect to TNF and ␣-Fas treatment were then calculated.
transfection combined with treatment with the proteasomal inhibitor MG132. Lysates were fractionated under denaturing conditions, and immunoblotting was performed using antibodies directed against E6. Figure 5A shows that when only the E6 large or the E6* gene was present, the corresponding protein was expressed and detected, migrating at apparent molecular masses of ϳ18 kDa and ϳ12 kDa, respectively. However, when the two isoforms were expressed together (HA-E6wt), several E6 complexes with higher molecular masses ranging from 40 to 75 kDa were detected. To verify complex formation between E6 large and E6*, we performed a coimmunoprecipitation experiment, transiently cotransfecting pHA-E6 large along with either vector or pFlag-E6*. It should be noted that the pFlag-E6* construct also includes the myc tag. E6 was immunoprecipitated using ␣-Flag agarose, and immunoblotting was performed using ␣-HA. Figure 5B (left) shows that HA-labeled E6 large was indeed detected in a complex with Flag-E6* at a molecular mass of ϳ50 kDa and that this 50-kDa band is absent when HA-E6 large is coexpressed with vector rather than with pFlag-E6*. The lower part of the filter was then overexposed (Fig.  5B , left, bottom insert) and showed a trace amount of the HA-E6 large monomer. To confirm the presence of E6* in the 50-kDa band, the filter was stripped and reprobed with ␣-cmyc (Fig. 5B, right) .
E6 complexes participate in pseudo-DISC formation following TNF-␣ induction. We previously demonstrated that E6 large can bind to the TNF R1 DD (11), while E6* can bind to procaspase 8 (9) . This led to the possibility that E6 large/E6* complexes could bind to both TNF R1 and procaspase 8, thus linking these molecules in a manner similar to that of the 5 cells/well were seeded onto a six-well plate, and MG132 (5 M) was then applied to cells for 16 h. Lysates were subjected to SDS-PAGE, and the detection of E6 was performed using ␣-E6 antibodies, normalized with antibodies directed against ␤-actin. (B) Response of cells expressing variable levels of E6 large or E6* to ␣-Fas and to TNF. The indicated cells, grown in the designated concentrations of Dox, were treated with ␣-Fas (10 ng/ml) or TNF (5 ng/ml) in the presence of Cx (5 g/ml) for 16 h. As a control, Utet cells were also treated with TNF and ␣-Fas. Viability was measured using the MTT assay. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means.
FIG. 5.
High levels of E6 large and E6*, expressed together, produce protein complexes with increased molecular masses. (A) Detection of complexes by immunoblotting. U2OS cells were transfected with pHA-E6wt, pHA-E6 large, and pHA-E6*. Thirty-two hours posttransfection, cells were treated with MG132 (5 M) for 16 h. Cell lysates were subjected to SDS-PAGE, and E6 was detected by immunoblotting. (B) Coimmunoprecipitation of complexes of ϳ50 kDa containing both E6 large and E6*. A total of 5 ϫ 10 6 U2OS cells were cotransfected with pFlag-E6* and HA-E6 large or vector and HA-E6 large. Cells were lysed in immunoprecipitation buffer lacking EDTA and dithiothreitol. Flag-E6* was immunoprecipitated (IP) from cell lysates using ␣-Flag-agarose. Following elution from the beads, proteins were subjected to SDS-PAGE, and the detection of E6 was performed using ␣-HA-HRP antibodies (left) and ␣-c-myc-HPR (right). Film was exposed for either 30 s (right top) or 5 min (bottom).
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on October 2, 2017 by guest http://jvi.asm.org/ adaptor complexes. If this were indeed the case, it might be possible to coprecipitate procaspase 8 using biotinylated TNF-␣. This approach is similar to that used previously to isolate the natural DISC following TNF or Fas induction of DISC formation (20) . To precipitate the DISC complex, we employed UtetE6wt cells, in which E6 expression can be regulated by Dox. In addition, cells not expressing E6, Utet cells, were used as a control. Cells were treated with biotinylated TNF-␣ for 30 min and were then lysed. Streptavidin beads, which bind to biotinylated TNF-␣, were then added to cleared lysates. Proteins that bound to TNF-␣ were separated by SDS-PAGE, transferred onto a membrane, and immunoblotted for procaspase 8, E6, TNF R1, and TNF-␣ (Fig. 6 ). Figure 6 (top) presents the amount of TNF-␣ bound to beads in each sample. The precipitated TNF R1 is also shown in Fig. 6 (second panel). E6 complexes are also shown and are detected only in E6-expressing cells (third panel). As expected, more E6 was precipitated in cells with a higher level of E6 expression; less E6 was detected at low levels of expression. Procaspase 8 (Fig.  6 , bottom) was coprecipitated by TNF-␣ primarily in cells expressing E6 at a high level. In cells expressing low levels of E6, only traces of precipitated procaspase 8 were detected, likely due to the reduced level of E6 complexes, while in cells not expressing E6, procaspase 8 was not precipitated at all. On the right side of Fig. 6 , the input levels of procaspase 8 and TNF R1 in the lysates are shown. These data demonstrate that E6 complexes are involved in the formation of DISC-like complexes following TNF-␣ stimulation. Only in cells expressing E6 is procaspase 8 coprecipitated, emphasizing the importance of the E6 large/E6* complex in linking TNF R1 with procaspase 8. The ability of E6 complexes of ϳ50 kDa, composed of one or more molecules of E6 large and E6* to bind both to TNF R1 and to procaspase 8 at the same time and thus to transmit the apoptotic signal, provides a plausible molecular explanation for the observed phenomenon of cell sensitization to TNF-induced apoptosis.
Both the levels and the ratio between E6 large and E6* are important in modulating TNF-and Fas-mediated apoptosis. At high levels of E6 expression, UtetE6wt cells are resistant to Fas-and sensitive to TNF-induced apoptosis (Fig. 1A) . The cells become sensitized to TNF treatment due to pseudo-DISC formation following TNF stimulation (Fig. 6) . At the same time, the reduced level of FADD leads to protection from Fas-induced apoptosis (Fig. 1A) . These observations suggest that the lack of FADD observed in cells was due to the activity of E6 large molecules and indicate that this lack of FADD is not important for pseudo-DISC formation following TNF stimulation. One prediction of this model is that if the level of E6 large were to be reduced, cells should become more sensitive to Fas treatment, while their response to TNF will depend on the ratio between E6 large and E6*. To test this prediction, the expression of E6 large was specifically reduced by the application of shRNA directed against E6 large. The shRNA was directed against the part of E6 that is present only in mRNA molecules coding for the full-sized isoform; therefore, only the transcripts encoding E6 large were affected, while mRNA molecules coding for the short version remained unaffected. We cloned the interfering RNA directed against E6 large into vector pSilencer 3.1. UtetE6wt cells, in which the level of E6 can be decreased by adding Dox to the growth medium, were then stably transfected with the plasmid, and the cell line UtetE6wt shE6L, where the expression of E6 large was partially inhibited, was isolated and characterized (Fig. 7A) . The control cell line UtetE6wt shCon was created following transfection with a scrambled sequence cloned into the same vector. The expression of E6 large was indeed knocked down by approximately 70% (Fig. 7A) , while the levels of expression of E6* at the level of both protein (Fig. 7B) and mRNA, as demonstrated by quantitative RT-PCR (Fig. 7C ) and semiquantitative RT-PCR (Fig. 7D) , were similar in both cell lines. The two cell lines were then examined for their response to ␣-Fas and to TNF. As predicted, the cell viability of UtetE6wt shE6L cells following Fas treatment was lower than that of the UtetE6wt shCon cells at each of the tested concentrations of Dox (Fig. 7E) . The viability of the UtetE6wt shE6L cells following TNF treatment was also lower than that seen with the control cells (Fig. 7F) .
It should also be noted that both cell lines became more resistant to TNF treatment at the lowest tested level of E6 expression (Fig. 7F) , providing evidence for the importance of the level of E6 in modulating the cellular response to TNF. The comparison between the two cell lines, on the other hand, where the ratio between the levels of E6 large and E6* expression was manipulated, provides evidence for the importance of the ratio between E6 large and E6*.
The level of E6 expression determines how cellular responses to TNF and Fas are modulated in NOK cells. The data presented above and in previous publications (7, 9) demonstrate that the modulation of TNF-and Fas-mediated apoptosis by E6 depends both on the level of E6 expression and on the ratio between E6 large and E6*. These experiments were originally performed using U2OS cells, which are derived from a FIG. 6. In the presence of high levels of E6 expression, a pseudo-DISC structure is formed in UtetE6wt cells following TNF-␣ stimulation. A total of 1 ϫ 10 7 cells were treated with 2 g of biotinylated TNF-␣ for 30 min. Protein complexes bound to TNF-␣ were precipitated by streptavidin agarose. Proteins were eluted from the streptavidin agarose and then subjected to separation by SDS-PAGE. Aliquots derived from cell lysates prior to precipitation were also loaded onto the gel (input). Biotinylated TNF-␣ was detected using antibodies directed against avidin-peroxidase (top), TNF R1 was detected using ␣-TNF R1 monoclonal antibodies (second panel), E6 complexes were detected using ␣-E6 antibodies (third panel), and procaspase 8 was detected with ␣-procaspase 8 (bottom).
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human osteosarcoma. To test whether similar events would occur in the natural target cells for HPV, keratinocytes, we transfected NOK cells with E6 and produced several cell lines that stably express HPV16 E6. NOK cells were originally derived by immortalization due to hTert expression (30) . The levels of E6 large and E6* expression were estimated by immunoblotting (Fig. 8A) , and the cells from clone 7 were found to express the highest level of both E6 species. The cells from clones 5 and 8 expressed approximately equivalent levels of E6 large, while cells from clone 5 expressed more E6* than did cells from clone 8. Cells from clone 9 expressed the lowest levels of E6 large and of E6*. The cellular responses of each of these cell lines to TNFand Fas-induced apoptosis were then estimated using a chemiluminescent caspase 3/7 assay (Fig. 8B and C) ; cell viability was also measured (Fig. 8D) . Cells from clone 7, expressing the FIG. 7. Inhibition of E6 large expression affects both Fas-and TNF-induced apoptosis. UtetE6wt cells were stably transfected with pSil shControl and pSil shE6 large in order to produce the UtetE6wt shCon and UtetE6wt shE6L cell lines. In the UtetE6wt shE6L cells, the hairpin RNA was directed only against E6 large. (A) In cells stably expressing shRNA directed against E6 large (UtetE6wt shE6L), the level of E6 large expression is lower than that in cells transfected with control shRNA (UtetE6wt shCon). A total of 7 ϫ 10 5 cells per well from each cell line were maintained at the indicated concentrations of Dox, and for 16 h prior to lysis, cells were treated with MG132 (5 M). The detection of HA-E6 large in lysates was performed by immunoblotting using ␣-E6 antibodies. (B) Expression levels of E6* were essentially equivalent between the UtetE6wt shCon and UtetE6wt shE6L cell lines. Expression was determined by immunoblotting as described above. (C and D) The level of the transcripts coding for E6 large decreases following shRNA treatment, while the level of transcripts coding for E6 I* and E6 II* remains unchanged. The level of transcripts was estimated by quantitative real-time PCR (C) and semiquantitative RT-PCR (D). (C) RNA was isolated from UtetE6wt shCon and UtetE6wt shE6L cells grown in medium without Dox or in the presence of 100 ng/ml of Dox, and cDNA was synthesized using the appropriate oligonucleotides (18) . Real-time PCR was performed using primers specific for each transcript, and GAPDH transcript amplification was used for normalization. (D) RNA from 1 ϫ 10 6 UtetE6wt shCon and UtetE6wt shE6L cells grown at the indicated concentrations of Dox was isolated, and RT-PCR was performed using primers designed for estimating the mRNA level for both E6 large and E6* transcripts (top) and Cfl-1 (bottom). (E and F) Decreases in the levels of expression of E6 large affect the cellular response to both ␣-Fas and TNF. A total of 7 ϫ 10 highest levels of both E6 species, were the most sensitive to TNF treatment even compared with cells not expressing E6 (NpLNCX). Caspase 3/7 activity was slightly reduced in cells from clone 5, which expresses less E6. Cells from clones 8 and 9 demonstrated the least activation of caspase 3/7 and were also resistant to TNF treatment ( Fig. 8B and D) .
When ␣-Fas, rather than TNF, was used as the activating agent, each of the clones demonstrated decreased activation of caspase 3/7 compared to the control cells (NpLNCX). As seen with TNF, the lowest level of caspase 3/7 activation was observed in cells derived from clones 8 and 9, where the expression of E6* was the lowest. In cells from clone 7, the activation of caspase 3/7 was only slightly decreased compared to that for control cells (Fig. 8C ). The viability assay shows relative protection in clones 5, 8, and 9, while viability in clone 7 is similar to that of the control cells (Fig. 8D) , a finding which mirrors the caspase activation assay (Fig. 8C) .
In conclusion, we have demonstrated that E6 expression can modulate cellular responses to TNF-and Fas-induced apoptosis in keratinocytes. The ability of E6 large to protect cells from Fas-induced apoptosis is influenced by the level of E6* expression, which in turn regulates E6 large activity (31, 32) . At high levels of both E6 large and E6* expression, cells become sensitive to TNF; at low levels of E6 expression, cells exhibit resistance to TNF treatment. This pattern is similar to that noted above for the U2OS-derived cells.
SiHa cells can be sensitized to Fas-induced apoptosis by overexpression of E6*. Two cervical cancer cell lines, Ca Ski and SiHa, each of which has integrated one or more copies of the entire genome of HPV16, differ significantly in their cellular responses to the engagement of the TNF-and Fas-mediated apoptotic pathways. Ca Ski cells are sensitive to TNF and Fas treatment, while SiHa cells are resistant to both cytokine treatments (Fig. 9A) . The level and ratio between E6 large and E6* expression in these two cell lines are presented in Fig. 9B (top). Our model predicts that the relatively high level of E6 large expression, combined with the absence of significant E6* expression, should provide protection from TNF-and Fasinduced apoptosis in SiHa cells. With regard to Ca Ski cells, the model predicts that the relatively high level of E6* would inhibit the protective activity of E6 large, leading to the increased sensitivity of these cells to both cytokines. Our data are consistent with this prediction (Fig. 9A and B ). Our working model is also supported by the observed levels of procaspase 8, FADD, and p53 in Ca Ski and SiHa cells. The level of procaspase 8 in Ca Ski cells is significantly higher than that in SiHa cells (Fig. 9B) , as is the level of FADD; this observation is consistent with the higher sensitivity of these cells to both TNF and ␣-Fas (Fig. 9A) .
One additional prediction of our model is that the overexpression of E6* in SiHa cells should sensitize SiHa cells to Fas-induced apoptosis, as this would change the ratio between 3 cells/well were cultured in a 96-well plate and were treated with TNF (50 ng/ml) or ␣-Fas (100 ng/ml) in the presence of Cx (0.25 g/ml) for 6 h the next day. The activity of caspase 3/7 was measured using the Caspase-Glo 3/7 assay (20 l of lysates in a total volume of 120 l). The level of caspase 3/7 activation was calculated as a percentage of the activity measured in cells treated with TNF or Fas compared to the activity measured in untreated cells. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. (D) A total of 7 ϫ 10 3 cells/well were cultured in a 96-well plate and were treated with TNF (50 ng/ml) or ␣-Fas (100 ng/ml) in the presence of Cx (0.25 g/ml) for 16 h the next day. Viability was measured using the CellTiter-Glo assay (Promega). Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. 4 cells/well were cultured in a 96-well plate and were treated with ␣-Fas (10 ng/ml) or TNF (5 ng/ml) in the presence of Cx (5 g/ml) for 16 h the next day. Viability was measured using the MTT assay. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. (B) The ratio between E6 large and E6* expression is shown by immunoblotting. E6 large expression obtained using antibodies directed against the C terminus of E6 is shown (top). The expression of both E6 large and E6* are shown where antibodies directed against the N terminus of E6 were used (second panel). Expression was normalized using antibodies directed against ␤-actin (third panel). Protein expression of p53 (fourth panel) and FADD (fifth panel), as normalized by ␤-actin (sixth panel), was detected in Ca Ski and SiHa cells. Cells were lysed following pretreatment with MG132 (5 M) for 16 h by immunoblotting using the corresponding antibodies. The expression level of procaspase 8 (seventh panel) was detected in cells not treated with MG132, normalized by ␤-actin (bottom). (C to E) SiHa cells were stably transfected with vector pFlag or with pFlagE6*. After G418 selection, the control pooled SFlag cell line as well as the SFlagE6* clone 13, 15, and 19 cell lines were created. (C) Activation of caspase 3/7 in response to TNF and ␣-Fas treatment. A total of 1 ϫ 10 4 cells/well were cultured in a 96-well plate and were treated with TNF (25 ng/ml) or ␣-Fas (50 ng/ml) in the presence of Cx (5 g/ml) for 6 h the next day. The activity of caspase 3/7 was measured using the Caspase-Glo 3/7 assay (20 l of lysates in a total volume of 120 l). The level of caspase 3/7 activation was calculated as a percentage of the activity measured in cells treated with TNF or Fas compared to the activity measured in untreated cells. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. (D) A total of 1 ϫ 10 4 cells/well were cultured in a 96-well plate and were treated with ␣-Fas (50 ng/ml) or TNF (25 ng/ml) in the presence of Cx (5 g/ml) for 16 h the next day. Viability was measured using the MTT assay. Each measurement was done in triplicate, and error bars indicate the standard deviations of the means. (E) Endogenous E6 large and FlagE6* expression levels in pooled SFlag cells and SFlagE6* clone 13, 15, and 19 cells were estimated by immunoblotting using ␣-E6 antibodies (top). The levels of p53 (second panel), procaspase 8 (third panel), FADD (fourth panel), and E7 (fifth panel), normalized by ␤-actin (bottom), were estimated by immunoblotting using the indicated antibodies. Prior to cell lysis, the cells were pretreated with MG132 (5 M) for 16 h. E6* and E6 large in favor of E6*. To test this, we stably transfected SiHa cells with pFlag E6*, created several clonal cell lines, and analyzed them for caspase activation and viability following treatment with TNF and Fas as well as for their expression of E6 large, E6*, p53, procaspase 8, and FADD. The data show that SiHa cells stably transfected with pFlagE6* do indeed experience higher levels of caspase 3/7 activation following treatment with Fas (over twofold for clone 19) and for clones 15 and 19 following treatment with TNF as well (Fig.  9C) . E6*-expressing SiHa cells can also became more sensitive to Fas than parental cells (Fig. 9D) . This effect is dependent on the level of E6* expression, with cells from clone 19, which express high levels of both isoforms, experiencing the greatest sensitization (Fig. 9D) . In Fig. 9E , the expression levels of endogenous E6 large and exogenous Flag-E6*, p53, procaspase 8, FADD, E7, and ␤-actin are shown for clones 13, 15, and 19. The endogenous expression of E6, p53, FADD, and E7 was detected only following the pretreatment of SiHa cells with the proteosomal inhibitor MG132. As noted above, the cells from clone 19, expressing relatively high levels of E6 large as well as the highest level of FlagE6*, were the most sensitive to Fas-induced apoptosis. These cells also expressed a higher level of the proapoptotic molecules procaspase 8, FADD, and p53, which could be accounted for by a decreased rate of degradation. This may be a result of the binding of exogenously expressed Flag-E6* to the endogenous E6 large and its subsequent inactivation. This capacity of E6* to decrease the ability of E6 large to mediate p53 degradation was previously demonstrated for HPV18 E6 (32) . Interestingly, the expression levels of E7 were the same in all cell lines.
The most straightforward explanation for this set of results is that by changing the ratio between E6 large and E6* expression in SiHa cells through the overexpression of E6*, we effected a measurable alteration in the cellular response to Fasinduced apoptosis. However, in spite of the increased levels of procaspase 8 and FADD, the overexpression of E6* only slightly sensitized the cells to TNF-induced apoptosis. The modest effect on TNF-induced apoptosis in SFlagE6* cells could be accounted for either because the pseudo-DISC is not efficiently formed in these cells, perhaps due to the expression of other HPV proteins, or because FlagE6* overexpression protects cells from TNF by mechanisms similar to those utilized in U2OS cells expressing E6* (Fig. 3 and 4) .
A pseudo-DISC structure was produced in NOK and Ca Ski cells expressing high levels of E6. The ability of E6 to sensitize NOK cells to TNF-induced apoptosis (clone 7) (Fig. 8A, B , and D) as well as the sensitivity of Ca Ski cells to TNF treatment (Fig. 9A) suggest that the pseudo-DISC could be formed as a result of TNF stimulation. To test this possibility, a coimmunoprecipitation of pseudo-DISC in these cell lines was performed. NOK cells not expressing E6 (NpLNCX), NOK cells expressing both isoforms of E6 at a high level (NE6wt), and Ca Ski cells were stimulated by the addition of biotinylated TNF-␣. The proteins bound to TNF-␣ were then pulled down with streptavidin-agarose and subjected to SDS-PAGE and immunoblot analysis. As expected, biotinylated TNF-␣ was bound to TNF R1 in all three cell lines, but procaspase 8 was precipitated only in cells expressing E6, that is, in the NE6wt and Ca Ski cells (Fig. 10A) . In cells not expressing E6, NpLNCX cells, procaspase 8 was not precipitated. Figure 10B demonstrates that E6 complexes were indeed formed in stably transected NE6wt cells. E6 was immunoprecipitated by ␣-Flag agarose and then detected using ␣-c-myc-HRP antibodies. E6 complexes of ϳ50 kDa were detected, corresponding to the same-sized complexes found following transient expression (Fig. 5B) .
Unfortunately, we were unable to directly detect the 50-kDa E6 complexes in this pseudo-DISC precipitation, as we did for the experiment shown in Fig. 6 . This may be due to the relatively low level of E6 expression in epithelial cells. The levels of were treated with 2 g/ml of biotinylated TNF-␣ for 30 min. Protein complexes bound to TNF-␣ were precipitated with streptavidin agarose. Proteins were eluted from the streptavidin agarose and then subjected to separation by SDS-PAGE. Aliquots derived from cell lysates prior to precipitation were also loaded onto the gel (input). Biotinylated TNF-␣ was detected using antibodies directed against avidin-peroxidase (top), TNF R1 was detected using ␣-TNF R1 monoclonal antibodies (middle), and procaspase 8 was detected with ␣-procaspase 8 monoclonal antibodies (bottom). (B) E6 protein complexes of ϳ50 kDa are formed in NE6wt clone 7 cells. A total of 7 ϫ 10 6 cells were lysed following MG132 pretreatment (5 M), and Flag-E6 proteins were precipitated with ␣-Flag agarose. Proteins were eluted from Flag-agarose and then subjected to separation by SDS-PAGE. E6 proteins were detected using ␣-c-myc-HRP antibodies. (Top) Thirty minutes of film exposure. (Bottom) Three minutes of film exposure. (C) Levels of E6 large expression in UtetE6L, UtetE6wt, Ca Ski, SiHa, and N E6wt clone 5, 7, 8, and 9 cells. Cell lysates were subjected to SDS-PAGE, and immunoblots were performed using antibodies directed against the E6 N-terminal protein (top). For E6 detection, cells were treated with 5 M MG132 for 16 h prior to lysate preparation, and loading was normalized by blotting for ␤-actin (bottom).
E6 expression in Ca Ski and SiHa cells (Fig. 10C, left) and NOK E6wt cells (Fig. 10C, right) were compared to the expression of E6 as seen in UtetE6L and in UtetE6wt cells. Clearly, in cells derived from U2OS cells, the level of E6 expression is much higher than that seen in epithelial cells.
DISCUSSION
Expression of HPV16 E6 modulates host cellular responses to TNF-and Fas-mediated apoptosis in a complex manner. Both the full-length E6 protein and E6* affect TNF-and Fasinduced apoptosis by binding to molecules involved in apoptotic pathways in ways that lead to either the stabilization or destabilization of their binding partners. Our studies have led to the conclusion that both the level of E6 expression and the ratio between the two E6 isoforms are important factors in determining how E6 expression can modify the cellular response to triggers of extrinsic apoptosis. The identification of the binding partners of E6 that are involved in extrinsic apoptotic pathways, combined with an analysis of the consequences of these interactions, has allowed us to develop a model of how TNF-and Fas-mediated apoptosis can be modulated by E6.
The simplest system in which to discuss the influence of E6 on cellular apoptotic pathways is the Fas-mediated apoptotic pathway. The higher the level of E6 large expression, the more protection from Fas-induced apoptosis is observed (10) . E6 large binds to both procaspase 8 and FADD and accelerates their degradation in a dose-dependent manner (9, 10) . By doing so, the ability of the cell to transmit apoptotic signals from Fas to effector caspases is impaired. In contrast, the expression of E6* appears to have little influence on the response of cells to ␣-Fas (Fig. 4B) , although E6* may indirectly influence Fas-induced apoptosis by binding to and inhibiting the activity of E6 large (Fig. 8) . This set of events is summarized in Fig. 11A and C.
The protection of E6-expressing cells from TNF is seen under three conditions:(i) only E6 large is expressed, (ii) only E6* is expressed, and (iii) very low levels of the wild-type gene (coding for both isoforms) are expressed (Fig. 11C ). There are several ways in which E6 large could, in principle, contribute to protection from TNF. It can bind to TNF R1, hindering it from binding to TRADD (11) ; it can bind to and mediate the degradation of FADD (10); and it can bind to and mediate the degradation of procaspase 8 (9) . Although the expression of E6* alone does not significantly influence the cellular response to Fas-induced apoptosis, it can also lead to protection from apoptosis induced by TNF (Fig. 3 and 4) . The binding of E6* to procaspase 8, through mechanisms not yet fully defined, prevents the transmission of the apoptotic signal from TNF R1 to procaspase 8 ( Fig. 3C and E and 4B), and this leads to the protection from TNF observed in cells expressing only E6*. Finally, when both isoforms are expressed at low levels, the cells are resistant to TNF (Fig. 1A and 8B and D) . E6 large probably contributes primarily by accelerating the degradation of procaspase 8. E6* likely also contributes to the TNF resistance of cells by mechanisms similar to those exhibited when it is expressed alone (Fig. 4B ). This set of events is summarized in Fig. 11B and C (bottom right).
Only when both isoforms are expressed in cells, and at levels ranging from moderate to high, is sensitization to TNF observed ( Fig. 1A and 8B and D) . The molecular explanation for this phenomenon may lie in the ability of the two isoforms to form complexes with each other (Fig. 5) . Because E6 large can bind to both TNF R1 and procaspase 8, as well as to E6*, and because E6* binds to procaspase 8 and to E6 large, it seemed likely that E6 complexes could link TNF R1 with procaspase 8, fulfilling the same role as the adaptor complex and functioning essentially as a "pseudo-DISC." To test the possibility that this pseudo-DISC existed, we undertook its isolation and were successful in showing that TNF-␣ was capable of pulling down TNF R1, E6 complexes of ϳ50 kDa, and procaspase 8, providing strong evidence that the proposed pseudo-DISC does form and is functional in U2OS cells (Fig. 6 ). We were also able to show that TNF-␣ was able to pull down TNF R1 and procaspase 8 in E6-expressing Ca Ski and NOK-E6 cells as well (Fig. 10A) , although we were unable to directly detect the E6 complexes in these pseudo-DISCs. This is likely due to limitations in the sensitivity of this immunoprecipitation protocol combined with comparatively low levels of TNF R1 and E6 expression in NOK and Ca Ski cells (Fig. 10C) . The exact composition of the ϳ50-kDa E6 complexes precipitated from pseudo-DISC is difficult to determine, but immunoprecipitation of separately tagged E6 large and E6* demonstrated that the ϳ50-kDa E6 complexes consist of one or more copies each of Flag-E6* and HA-E6 large (Fig. 5B ). This set of events is summarized in Fig. 11B (lower left) as well as in Fig. 11C . Together, these observations have led to the conclusion that the cellular response to TNF and to Fas depends on both the level of E6 and the ratio between the two isoforms.
The importance of the ratio between E6 large and E6* with regard to the cellular response to TNF-and Fas-induced apoptosis is summarized in Fig. 11C . If E6* is present at a low level or is absent, cells become resistant to TNF primarily due to the degradation of procaspase 8 resulting from E6 large binding. In addition, a low level of E6* expression can also contribute to protection from TNF. Meanwhile, the cellular response to Fas is related to the level of E6 large in a dose-dependent manner (Fig. 11C, top) . If E6 large is expressed at a low level or is absent, cells become resistant to TNF due to E6* expression. In contrast, the cellular response to ␣-Fas is not directly or significantly affected by E6* expression (Fig. 11C, middle) . If E6 large and E6* are both present at low levels of expression, cells are resistant to TNF and somewhat resistant to Fas. If the expression level of both isoforms is increased, cells become more resistant to Fas due to the increasing level of E6 large. Meanwhile, with this increased level of E6 large and E6* comes the ability to form the E6 complexes that are capable of binding to TNF R1 and procaspase 8 at the same time. As a result of this pseudo-DISC formation, cells become sensitive to TNF. The binding of E6* to E6 large also inactivates the ability of E6 large to accelerate the degradation of proapoptotic molecules, and at the highest levels of expression, cells could therefore become less protected from Fas (Fig. 11C, bottom) .
It was reported that in HPV18, another high-risk strain, the binding of E6* to E6 large inhibits the activity of E6 large by reducing its ability to degrade p53 (13, 17, 31, 32) . In this report, we found that the binding of E6* to E6 large can reduce the protective effect of E6 large on Fas-mediated apoptosis (Fig. 9C, D , and E) by inhibiting an activity other than the degradation of p53. These interactions are particularly inter- esting in NOK cells, keratinocytes which are very similar to the natural hosts for HPVs, as well as in Ca Ski and SiHa cells, which are cell lines derived from HPV-associated cervical cancers. The results obtained from our experiments with these cells (Fig. 8, 9 , and 10) support those obtained from our work in the U2OS cell line, providing further evidence that both the levels and ratios of E6 isoform expression strongly influence the response of these cells to mediators of the TNF and Fas apoptotic pathways and that E6* can limit the activity of E6 large. In particular, we were able to show in NOK cells that the expression of E6 large in the absence of E6* inhibited the activation of caspase 3/7 following the engagement of the TNF and Fas apoptotic pathways, that the expression of E6* abrogated this protection to some extent, and that when both isoforms were present at high levels, cells could be sensitized to TNF (Fig. 8) . Furthermore, we were able to demonstrate that only in the presence of E6 was biotinylated TNF capable of coimmunoprecipitating procaspase 8 ( Fig. 10A and B) .
One interesting observation made from the cervical cancer lines is that Ca Ski cells are much more sensitive to both TNF and to ␣-Fas than are SiHa cells (Fig. 9A) . The difference between these cell lines is in the level of E6* expression. In SiHa cells, the expression of E6* is undetectable using our immunoblot protocol, while in Ca Ski cells, the level of E6* expression is relatively high (Fig. 9B) . The E6 large that is present in SiHa cells appears to be better able to mediate the rapid degradation of p53, procaspase 8, and FADD than is the E6 large that is present in Ca Ski cells (Fig. 9B) , which is likely due to the inhibition of E6 large activity by the E6* that is present in Ca Ski (but not SiHa) cells. With regard to their response to treatment with TNF, the difference in the two cell lines could be explained by a higher level of procaspase 8 in the Ca Ski cells (Fig. 9A) , combined with the formation of a pseudo-DISC in which E6 large and E6* most likely combine to produce complexes that have the potential to link TNF R1 with procaspase 8 (Fig. 10 ). As noted above, the coimmunoprecipitation of procaspase 8 with biotinylated TNF was successful only in cells expressing E6, supporting the idea that the E6 complexes provide a physical link between TNF R1 and other elements of the signal transduction complex. With respect to their response to ␣-Fas, the relative sensitivity of Ca Ski cells correlates well with the higher level of FADD and procaspase 8 in these cells (Fig. 9A and B) , which is likely due to an inability of E6 large to accelerate their degradation as a result of binding to E6*. The cellular response of Ca Ski cells to ␣-Fas is similar to the cellular response to Fas of the UtetE6wt shE6L cells (Fig. 7E) , where a decreased level of expression of E6 large sensitized these cells as well to Fas-mediated apoptosis. We were also able to demonstrate an increased level of procaspase 8 and FADD and, hence, sensitization to Fas treatment in SiHa cells as a result of the exogenous expression of Flag-E6* (Fig. 9C, D , and E). It should also be noted that in the cervical cancer cell lines Ca Ski and SiHa, the entire genome of HPV16 is present. It may be that other HPV proteins, such as E7, also influence the cellular response to TNF and ␣-Fas (27, 38) . Our data support the idea that the E6 expressed in Ca Ski and SiHa cells contributes to the cellular response to TNF and Fas-mediated apoptosis, which depends upon both the level of the two E6 isoforms and the ratio between them. The conclusion that we draw from the Ca Ski and SiHa cells is that the system is more complex and interesting than previously thought, pointing to additional levels of control and consistent with the idea that E6* can regulate the activity of E6 large.
In addition to the E6 large functional modulations that result from E6* binding, the complexes of ϳ50 kDa that are formed between E6 large and E6* have the potential to acquire novel properties. In this report, we present data demonstrating that E6 complexes, which are stable under the denaturing conditions of SDS-PAGE, have acquired a new property, namely, the sensitization of cells to TNF, compared to the properties of either isoform as assayed separately. To the best of our knowledge, this is the first demonstration that E6 complexes with novel functional and biological properties can be formed between E6 large and E6*. The exact molecular composition of other E6 complexes is an area of continuing study.
Experiments employing the accelerated degradation of FADD by E6 large (10) have demonstrated that the adaptor protein FADD is required for Fas-induced apoptosis but may not be critical for TNF-induced apoptosis. The importance of FADD in TNF-mediated apoptosis is still in debate (39) . One explanation for the relative insensitivity of the TNF-mediated pathway to decreasing levels of FADD may be that the level of FADD reduction that can be achieved with E6 large expression may not be sufficient to significantly influence TNF apoptosis. This explanation would imply that the level of FADD that is necessary for signal transduction is much higher in the Fasmediated pathway than in the TNF-mediated pathway.
The difference between TNF and Fas signal transduction lies in the initiating signal transduction events. Upon Fas stimulation, the adaptor protein FADD and procaspase 8 are recruited to the Fas DD, resulting in DISC formation. Conformational changes of proteins in the DISC lead to the cleavage of procaspase 8 and initiate the caspase cascade in cells (Fig.  11A, right) . The TNF signaling pathway, however, requires the formation of two distinct signaling complexes (29) . Following TNF stimulation, procaspase 8 and FADD are not initially recruited to the DISC. Rather, a complex consisting of TRADD, RIP1, and TRAF2 is formed (complex 1) (Fig. 11B,  top) . As a result of conformational changes, complex 1 then dissociates from TNF R1 and produces complex II, which in turn recruits both FADD and procaspase 8 (29) . These same two phases of the initial step in TNF-induced apoptosis were confirmed in other studies (20, 24) . The data presented in Fig.  6 , where the components of DISC in E6-expressing, TNFsensitive cells were coprecipitated with biotinylated TNF-␣, demonstrate that E6 complexes are directly involved in DISC formation and that procaspase 8 is recruited to this pseudo-DISC. The absence of procaspase 8 in the DISC of cells not expressing E6 supports the idea that procaspase 8 is not present in the normal DISC. If the level of E6 expression in these same cells is reduced, procaspase 8 is barely precipitated (Fig. 6) . Similar results were noted for NOK and Ca Ski cells (Fig. 10A and B) . These data provide an important demonstration of how viral proteins can create a novel, functional protein complex in host cells. In fact, the virally derived pseudo-DISC appears to be more effective in transmission of the apoptotic signal from TNF R1 to procaspase 8 than is the host machinery. VOL. 83, 2009 HPV16 E6-ASSOCIATED PSEUDO-DISC STRUCTURES 225
As we have observed, a low level of E6 expression, such as that observed early in infection, leads to significant protection from TNF-induced apoptosis as well as to some protection from Fas (Fig. 1A and B) . Once the genome of HPV becomes integrated into the host chromosome, especially in situations where the linearization of the viral genome occurs within the E2 gene, the expression of E2 is likely to decrease, thereby freeing the E6 and E7 genes from E2-mediated negative regulation. In addition, oncogene expression can be upregulated by host regulatory elements present in the integration locus, and the production of splice isoforms of E6 may also be under the control of regulatory elements near the site of integration. These factors all have the potential to lead to polymorphisms in the ratio between E6 large and E6*.
Etiological studies of actual cases of cervical cancer have shown that the differential splicing of the E6/E7 region of HPV16 or HPV18 can be used as a marker of risk for cervical cancer development and also for the likely response to treatment (2, 5) . For example, it was shown that the most aggressive type of cancer, with an unfavorable prognosis for treatment and affecting primarily young women, is characterized by the Asian-Amerindian variant of E6. This variant is characterized by a low level of E6* expression and a high level of E6 large expression at the transcriptional level. In the African variant of E6, which is less aggressive, the expression of a high level of E6* was observed, which coincided with higher levels of p53. Those authors connected the difference in cancer aggressiveness and prognosis for treatment with the expression of E6*, which decreases the binding of E6 large to E6AP (2) . In our study, we found that a low level of E6* expression combined with a high level of E6 large led to resistance to both TNF-and Fas-induced apoptosis, a situation predicted to be unfavorable for prognosis and treatment. Such an increased level of expression of E6 large with respect to E6* may be one factor contributing to the aggressiveness of some cervical cancers. However, it is known that cervical cancer can develop even in the presence of high levels of E6* expression as determined by RT-PCR (2, 5) . The development of a more complete understanding of the oncogenic properties of E6* thus remains a task for future studies.
In summary, our studies of the influence of E6 isoforms on apoptosis induced by members of the TNF superfamily have allowed us to develop a model of molecular mechanisms that explains and clarifies a body of data that previously appeared to be unconnected, paradoxical, and somewhat inconsistent. This model has uncovered intricate interrelations between the E6 isoforms and shown that by forming complexes, the proteins can acquire new functional properties. The application of this model to natural cervical cancer cells, in which the HPV genome has been integrated, demonstrates that it can explain the difference in the response of these cervical cells to apoptotic stimuli. However, dissecting out the individual contributions of each of the HPV isoforms and proteins in the complex system of actual human cancers remains a task for future studies.
